Anti CD25 treatment of human dendritic cells modulates both their cytokine synthesis profiles and their capacity to activate allogeneic CD4 T cells: a potential tolerogenic effect.
Recently, attention has been focused on the role for dendritic cells (DCs) in the promotion of peripheral tolerance. It is currently believed that the maturation/activation state of DCs might be a control point for the induction of graft tolerance through modifications of the activation state of T cells. We have observed IL-2, and IL-2 receptor gene expression by reverse transcriptase-polymerase chain reaction (RT-PCR) in human DC lysates following bacterial stimulation. It has been demonstrated in the present study IL-2R alpha (CD25) expression on human DCs upon LPS activation. DCs differentiated from monocytes were exposed to anti CD25 during maturation, anti CD25 treatment affected the abilities of human DCs to induce CD4+ T cell proliferation in response to alloantigens, maintained endocytic capacity, Anti CD25 treated DCs produce low levels of IL-12 and IFN and high level of IL-10. All these characteristics suggest that DCs may be used in cellular therapy either to induce allograft tolerance (anti CD25 treated DCs) or to restore immunity against tumors (IL-2 treated DCs).